araag2/HINT huggingface dataset:
Clinical trial NCT00477711 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, cisplatin, capecitabine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Having signed informed consent

          -  Age 18 to 75 years old

          -  Histologically confirmed gastric adenocarcinoma

          -  Unresectable recurrent or metastatic disease

          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more
             than 12 months

          -  Measurable disease according to the RECIST criteria

          -  Karnofsky performance status ≥60

          -  Life expectancy of ≥2 month

          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than
             4 weeks

          -  ALT and AST<2.5 times ULN (≤5 times ULN in patients with liver metastases)

          -  Serum albumin level ≥3.0g/dL

          -  Serum AKP < 2.5 times ULN

          -  Serum creatinine <1.5mg/dL

          -  Bilirubin level < 1.5mg/dL

          -  Serum creatinine <1.5 times ULN

          -  WBC>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3, Hb>9g/dl

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous systemic therapy for metastatic gastric cancer

          -  Inability to take oral medication

          -  Previous EGFR pathway-targeting therapy

          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

          -  Heart failure, coronary artery disease, myocardial infarction within the last 6 months

          -  Known allergy to any study treatment

          -  Pregnancy or lactation period

          -  Any investigational agent within the past 28 days

          -  Other previous malignancy within 5 year, except non-melanoma skin cancer

          -  Previous adjuvant therapy with capecitabine+platinum

          -  Pre-existing neuropathy>grade 1

          -  Legal incapacity
Clinical trial NCT00168701 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: bg00012
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Must be 18 to 55 years old, inclusive, at the time of informed consent.

          2. Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald
             criteria #1-4 (McDonald et al, 2001; Appendix 2).

          3. Must have a baseline EDSS between 0.0 and 5.0, inclusive.

        5. Must have experienced at least one relapse within the 12 months prior to randomization,
        with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of
        Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.

        6. Male and female subjects must be willing to take appropriate measures to prevent
        pregnancy.

        Exclusion Criteria:

          1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by
             Lublin and Reingold, 1996 [Appendix 3]).

          2. History of malignancy.

          3. History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

          4. History of abnormal laboratory results indicative of any significant cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or
             other major disease.

          5. History of human immunodeficiency virus (HIV).

          6. History of drug or alcohol abuse (as defined by the Investigator) within the 2 years
             prior to randomization.

          7. An MS relapse that has occurred within the 50 days prior to randomization AND/OR the
             subject has not stabilized from a previous relapse prior to randomization.

          8. Body weight >100 kg.

          9. Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen
             (HBsAg) at screening.

         10. Any of the following abnormal blood tests at screening.

         11. Any previous treatment with FUMADERM®, FAG-201, or BG00012.

         12. A medication history that precludes entry into the study.

         13. Female subjects who are currently pregnant or breast-feeding.
Clinical trial NCT00316771 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: p38 inhibitor (4) 150mg, p38 inhibitor (4) 25mg, p38 inhibitor (4) 300mg, p38 inhibitor (4) 50mg, p38 inhibitor (4) 75mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  active rheumatoid arthritis;

          -  current inadequate clinical response to methotrexate.

        Exclusion Criteria:

          -  receiving any other disease-modifying anti-rheumatic drug, with the exception of
             hydroxychloroquine or chloroquine.
Clinical trial NCT01255592 (phase 2, status: completed)
Conditions: bronchiectasis, lung disease, respiratory diseases
ICD codes: J47.9, Q33.4, J47.1, J47.0, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, J84.115, J39.9, J44.0, P27.9, B97.4, J39.8, J99
Drugs: azd5069, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male, or female of non-child bearing potential; ie, women who are permanently or
             surgically sterilised or post-menopausal.

          -  Aged 18 to 80 years inclusive at screening (Visit 1)

          -  Have a clinical diagnosis of idiopathic or post infective bronchiectasis as diagnosed
             with a historical high resolution computerised tomography (HRCT) or bronchogram

          -  Be sputum producers with a history of chronic expectoration on most days of most weeks
             of the year. Patients should have a history of spontaneously producing sputum on a
             daily basis and should be able to provide at least 2 of the 3 required baseline sputum
             samples with an average of 3 mL or more.

          -  Be on a stable treatment regimen, as judged by the investigator.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Patients with other latent or chronic infections or at risk of infection within 90
             days before Visit 2

          -  An acute exacerbation or acute respiratory infection (upper or lower) requiring oral
             steroids or antibiotics within 30 days prior to Visit 2

          -  An FEV1 of <30% of predicted normal at Visit 1

          -  Patients who have received live or live-attenuated vaccine in the 2 weeks prior to
             dosing (Visit 2)

          -  Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or
             COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis

          -  Bronchiectasis associated with a generalised immunodeficiency disorder, where
             manifestations other than bronchiectasis predominate
Clinical trial NCT01619839 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: nktr-181, placebo
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CC[C@]2([H])OCCOCCOCCOCCOCCOCCOC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give written informed consent;

          -  Willing and able to understand the study procedures, and comply with all study
             procedures;

          -  Females or males, age ≥ 18 years old;

          -  Body mass index 18-39, inclusive;

          -  In good general health;

          -  Clinical diagnosis of OA in one or both knees;

          -  Have been on a stable regimen of pain medication for the management of OA knee pain;

          -  Not experiencing adequate pain relief with their current dosing regimen;

          -  Women of childbearing potential (WCBP) must agree to use highly effective methods of
             birth control. Male subjects must agree to use contraception.

        Exclusion Criteria:

          -  Females who are pregnant or lactating;

          -  Known history of hypersensitivity, intolerance, or allergy to opioids;

          -  Diagnosed as having any chronic pain symptom that in the Investigator's opinion would
             interfere with the assessment of pain and other symptoms of OA;

          -  Presence of any medical condition that would preclude study participation in the
             opinion of the investigator;

          -  Clinically significant abnormalities of vital signs or clinical laboratory results;

          -  Clinically significant electrocardiographic abnormalities;

          -  Received systemic corticosteroids within 30 days prior to signing the consent form;

          -  Subjects who are known or suspected to be currently abusing alcohol or drugs;

          -  Positive urine drug screen, or alcohol breath test during Screening Period testing;

          -  Positive serology for the surface antigen of Hepatitis B (HBsAg) or Hepatitis C
             (anti-HCV) during Screening Period testing;

          -  Known to be human immunodeficiency virus (HIV) positive;

          -  Donation of blood or plasma within 30 days prior to signing the consent form;

          -  Participation in another drug or biologic study within 30 days prior to signing the
             consent form;

          -  Any other reason that, in the opinion of the Investigator or Medical Monitor, would
             render the subject unsuitable for participation in the study.
Clinical trial NCT00565448 (phase 2, status: completed)
Conditions: nasopharyngeal neoplasms, carcinoma
ICD codes: A36.1, B87.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: docetaxel, cisplatin, 5-fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of nasopharyngeal carcinoma World Health Organization (WHO)
             type II or III

          -  Children and adolescents newly diagnosed with Stage IIB-IV NPC with measurable
             disease, who are >1 month to ≤21 years of age at the time of diagnosis. In France,
             participants must be ≥1 year to ≤21 years of age at the time of diagnosis

        Exclusion Criteria:

          -  Participants with short life expectancy

          -  Prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of
             nasopharyngeal carcinoma

          -  Inadequate renal function evidenced by unacceptable laboratory results

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00700206 (phase 2, status: completed)
Conditions: myelodysplastic syndrome (mds)
ICD codes: D46.Z, D46.9, C94.6, D46.C
Drugs: ezatiostat hydrochloride
SMILES: CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary or de novo MDS

          -  Low or intermediate-1 MDS

          -  ECOG performance status 0 or 1

          -  Documented significant anemia with or without neutropenia and/or thrombocytopenia

          -  Adequate kidney and liver function

          -  Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to
             study entry

        Exclusion Criteria:

          -  Prior allogenic bone marrow transplant for MDS

          -  History of MDS IPSS score greater than 1.0

          -  Pregnant or lactating women

          -  Any severe concurrent disease, infection, or comorbidity that, in the judgement of the
             investigator, would make the patient inappropriate for study entry

          -  Oral steroids e.g. prednisone >10 mg per day

          -  History of active hepatitis B or C

          -  Known history of HIV
Clinical trial NCT00672594 (phase 2, status: completed)
Conditions: prostate cancer, prostatectomy
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: sunitinib malate
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic evidence of adenocarcinoma of the prostate deemed candidates for curative
             RRP

          -  Intermediate or high risk, clinically localized disease

          -  Adequate organ function

          -  Patients must be surgically sterile or must agree to use effective contraception
             during the period of therapy

          -  Select imaging to rule out metastasis will be done as clinically indicated

          -  Signed and date informed consent document

        Exclusion Criteria:

          -  Prior treatment for prostate cancer

          -  Major surgery or radiation therapy within 4 weeks of starting the study treatment

          -  NCI CTCAE grade 3 hemorrhage within 4 weeks of starting therapy

          -  History of or known metastatic prostate cancer

          -  Any of the following within the 6 months prior to study drug administration:
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack, or pulmonary embolism.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade 2 or greater

          -  QTc interval > 500 msec on baseline EKG

          -  Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal
             medical therapy).

          -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication

          -  Known active infection

          -  Concurrent treatment on another clinical trial. Supportive care trials or
             non-treatment trials, e.g. QOL, are allowed.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study.
Clinical trial NCT00000811 (phase 2, status: completed)
Conditions: bacterial infections, pneumonia, pneumocystis carinii, hiv infections
ICD codes: A49.9, A04.9, A04.8, A49.8, Z21
Drugs: azithromycin, atovaquone, sulfamethoxazole-trimethoprim
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
Eligibility criteria:

        Inclusion Criteria

        Children may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are between the age of 3 months and 18 months (consent of parent or guardian
             required). (This study has been changed. In an earlier version, patients up to 19
             years old were eligible.)

          -  Are at risk for developing pneumonia and need preventive treatment.

          -  Have a CD4 count of less than 1,500 cells/mm3 if under 1 year of age or a CD4 count of
             less then 500 cells/mm3 if between 1 and 2 years of age.

        Exclusion Criteria

        Children will not be eligible for this study if they:

          -  Have an infection that requires treatment.

          -  Are allergic to atovaquone, azithromycin, or SMX/TMP.

          -  Have serious diarrhea for more than 1 week.
Clinical trial NCT00338455 (phase 2, status: terminated)
Conditions: congestive heart failure, cardiac transplantation, renal insufficiency, renal failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40, M31.11, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1, P96.0, O03.32, O04.82, O08.4, O03.82, O07.32, I13.11
Drugs: natrecor (nesiritide)+standard care+dobutamine or milrinone, placebo+standard care+dobutamine or milrinone
SMILES: CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1, CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
Reason stopped: 
    dsmc acknowledged no safety concerns with the trial, recommending that the trial be terminated
    due to slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Meet the criteria for a United Network for Organ Sharing (UNOS) Status 1B heart
             transplant candidate, or, if outside the US, have comparable status

          -  must also be a primary transplant candidate waiting to receive a single cardiac
             allograft

          -  must be receiving continuous intravenous infusion of dobutamine or milrinone through a
             double-lumen central catheter or a double-lumen percutaneously inserted central
             catheter for at least 3 consecutive days before randomization

          -  must be willing and able to participate in the study assessments and follow up
             procedures

          -  male and female subjects of childbearing potential agree to use two highly effective
             methods of birth control for the duration of the study.

        Exclusion Criteria:

          -  Not have systolic blood pressure (SBP) consistently < 80 mm Hg, or have clinically
             significant orthostatic hypotension

          -  not weigh > 130 kg

          -  not have a ventricular assist device (VAD), or anticipate the need for a VAD, during
             the 28-day study drug treatment period

          -  not have received placement of an internal cardiac defibrillator (ICD) or external
             cardiac defibrillator (ECD) within 72 hours before randomization

          -  not require chronic hemodialysis or peritoneal dialysis to treat renal failure, or had
             acute dialysis or ultrafiltration within 7 days before randomization

          -  not have received antibiotic treatment within 7 days before randomization-antibiotics
             are permissible for any prophylactic use.
Clinical trial NCT00193089 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, vinorelbine, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Metastatic breast cancer confirmed by biopsy

          -  Overexpression of the Her-2 oncogene

          -  Age > 18 years

          -  Measurable disease

          -  Able to perform activities of daily living with minimal assistance

          -  No previous chemotherapy for metastatic disease

          -  One or more previous hormonal therapies for metastatic disease.

          -  Adequate bone marrow, liver and kidney function

          -  Patients with < grade 1 peripheral neuropathy are eligible.

          -  Must give written informed consent prior to entering this study.

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Abnormal heart function

          -  Previous treatment with trastuzumab

          -  Brain metastases untreated

          -  Pre-existing symptomatic peripheral neuropathy

          -  Serious underlying medical conditions

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT01709318 (phase 2, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: nomegestrol acetate (nomac), etonogestrel (eng), ethinyl estradiol (ee), estradiol (e2)
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index (BMI) ≥18 and ≤35

          -  Regular cycles from 24 to 35 days in length, with an intra-individual variation of ±3
             days permitted within this range

          -  Good physical and mental health

        Exclusion Criteria:

          -  Diabetes mellitus with vascular involvement

          -  Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis

          -  Severe dyslipoproteinemia

          -  Severe hypertension

          -  Presence or history of pancreatitis associated with severe hypertriglyceridaemia

          -  Presence or history of severe hepatic disease

          -  Undiagnosed vaginal bleeding

          -  Known or suspected pregnancy

          -  Participation in another investigational drug study within 30 days prior to screening
             visit

          -  History of malignancy ≤5 years, except for adequately treated basal cell or squamous
             cell skin cancer, or in situ cervical cancer

          -  Documented abnormal cervical smear result in 6 months prior to screening visit

          -  Sterilization using a fallopian tube occlusion device (e.g., Essure method)

          -  Sex hormone therapy within 2 months prior to screening visit for purpose other than
             contraception, or injectable hormonal contraception within 6 months prior to screening
Clinical trial NCT00530166 (phase 2, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: jnj-18054478, sham comparator
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O
Reason stopped: 
    lack of efficacy following an interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Medically confirmed diagnosis of persistent asthma

          -  Able to demonstrate reversibility of at least 12% with albuterol inhalation

          -  Use of short-acting b-2 agonists for rescue >= 5 times within 2 weeks prior

          -  Able to produce an FEV1 between 45 and 85% of predicted

          -  Willing to perform study procedures for about 14 weeks.

        Exclusion Criteria:

          -  Use of inhaled corticosteroids within 4 weeks

          -  Use of oral/parenteral corticosteroids within 8 weeks

          -  Use of long-acting beta-2 agonists or montelukast within 2 weeks

          -  History of life-threatening asthma attack within 3 months

          -  Female of child bearing potential.